SG10201705061RA - Treatment of Diseases of Endothelial Dysfunction and Inflammation - Google Patents

Treatment of Diseases of Endothelial Dysfunction and Inflammation

Info

Publication number
SG10201705061RA
SG10201705061RA SG10201705061RA SG10201705061RA SG10201705061RA SG 10201705061R A SG10201705061R A SG 10201705061RA SG 10201705061R A SG10201705061R A SG 10201705061RA SG 10201705061R A SG10201705061R A SG 10201705061RA SG 10201705061R A SG10201705061R A SG 10201705061RA
Authority
SG
Singapore
Prior art keywords
inflammation
diseases
treatment
endothelial dysfunction
dysfunction
Prior art date
Application number
SG10201705061RA
Inventor
Itescu Silviu
Ghosh Peter
Gregory KIMPTON Wayne
Reeves Bailey Simon
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of SG10201705061RA publication Critical patent/SG10201705061RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
SG10201705061RA 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation SG10201705061RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12

Publications (1)

Publication Number Publication Date
SG10201705061RA true SG10201705061RA (en) 2017-07-28

Family

ID=50933585

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201705061RA SG10201705061RA (en) 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation
SG11201504340YA SG11201504340YA (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201504340YA SG11201504340YA (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Country Status (12)

Country Link
US (2) US20160175360A1 (en)
EP (2) EP2931876B1 (en)
JP (4) JP6572130B2 (en)
KR (3) KR102506612B1 (en)
CN (2) CN111840329A (en)
AU (3) AU2013360024B2 (en)
CA (1) CA2893942C (en)
ES (1) ES2742035T3 (en)
HK (1) HK1210209A1 (en)
IL (1) IL239308A0 (en)
SG (2) SG10201705061RA (en)
WO (1) WO2014089623A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939417B (en) 2007-12-04 2014-02-05 蛋白生物动力私人有限公司 Protection of progenitor cells and regulation of their differentiation
JPWO2022114111A1 (en) * 2020-11-27 2022-06-02

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE530180T1 (en) 1997-04-02 2011-11-15 Brigham & Womens Hospital METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (en) 1999-08-21 2003-06-18 Schott Glas Skull crucible for melting or refining inorganic substances, especially glasses and glass ceramics
JP5265190B2 (en) 2004-09-24 2013-08-14 メソブラスト,インコーポレーテッド Pluripotent proliferating mesenchymal progenitor progeny (MEMP) and uses thereof
KR101617319B1 (en) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
JP2008544957A (en) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ Treatment of renal diseases and multiple organ failure by mesenchymal stem cells and mesenchymal stem cell conditioned medium
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
CN101939417B (en) * 2007-12-04 2014-02-05 蛋白生物动力私人有限公司 Protection of progenitor cells and regulation of their differentiation
US20110200612A1 (en) * 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
EP3002329B1 (en) * 2008-11-20 2017-08-16 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
US20120195969A1 (en) * 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
AU2012262675B2 (en) * 2011-06-03 2016-05-19 Mesoblast, Inc Methods of treating or preventing neurological diseases
CN110051693A (en) * 2011-07-04 2019-07-26 麦瑟布莱斯特公司 The method for treating or preventing rheumatic disease
CA2880808C (en) * 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
ES2697573T3 (en) * 2013-01-09 2019-01-25 United Therapeutics Corp Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Also Published As

Publication number Publication date
CN111840329A (en) 2020-10-30
CA2893942A1 (en) 2014-06-19
JP2023030116A (en) 2023-03-07
AU2013360024A1 (en) 2015-07-02
AU2019202960A1 (en) 2019-05-16
EP2931876A4 (en) 2016-05-25
EP2931876B1 (en) 2019-05-29
EP3556850A1 (en) 2019-10-23
WO2014089623A1 (en) 2014-06-19
KR20150093732A (en) 2015-08-18
KR102217962B1 (en) 2021-02-22
JP6572130B2 (en) 2019-09-04
HK1210209A1 (en) 2016-04-15
KR20220029758A (en) 2022-03-08
AU2019202960B2 (en) 2021-07-29
EP2931876A1 (en) 2015-10-21
JP7201715B2 (en) 2023-01-10
CN105358163B (en) 2020-09-11
KR102506612B1 (en) 2023-03-06
JP2019214571A (en) 2019-12-19
CN105358163A (en) 2016-02-24
CA2893942C (en) 2023-03-28
SG11201504340YA (en) 2015-07-30
US20160175360A1 (en) 2016-06-23
AU2021250848A1 (en) 2021-11-04
KR102367981B1 (en) 2022-02-25
ES2742035T3 (en) 2020-02-12
JP6829288B2 (en) 2021-02-10
AU2013360024B2 (en) 2019-02-28
JP2016504311A (en) 2016-02-12
JP2021073240A (en) 2021-05-13
US20240115618A1 (en) 2024-04-11
IL239308A0 (en) 2015-07-30
KR20210021104A (en) 2021-02-24

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases
HK1211474A1 (en) Treatment of immune-related and inflammatory diseases
HK1198631A1 (en) Prevention and treatment of ocular conditions
EP2670434A4 (en) Treatment of tauopathies
HK1199015A1 (en) Treatment of inflammation
EP2723347A4 (en) Prevention and treatment of inflammatory conditions
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
HK1220352A1 (en) Il-33 and treatment of neurodegenerative diseases il-33
HK1211213A1 (en) Treatment of diseases involving mucin
HK1204573A1 (en) Treatment of inflammatory skin disorders
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1213175A1 (en) Treatment and/or prophylaxis of tspo mediated diseases and/or disorders tspo //
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2710017A4 (en) Macrocycllc therapeutic agents and methods of treatment
HK1210209A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
HK1198121A1 (en) Therapeutic combinations of netupitant and palonosetron
GB201100651D0 (en) Treatment of inflammation
AU2012900272A0 (en) Treatment and inhibition of corneal erosions
GB201201779D0 (en) Treatment of inflammatory disorders